On December 19, 2023, Hasten’s CEO Summer XIA, Vice President and Head of Commercial Excellence Hanson Zheng and other senior leaders from Hasten visited Shenzhen China Resources Gosun Pharmaceutical Co., Ltd. (CR Gosun), and signed a MOU for the deep collaboration with CR Gosun.

When talking about the collaboration, Summer Xia said, "Hasten has acquired 7 classic originator drugs and has been able to make these drugs benefit to a wide range of Chinese patients through its excellent commercialization capabilities. CR Gosun is well known in the industry for its advanced manufacturing facilities, stringent quality management system and high-quality products. I am confident that by leveraging our mutual strengths, we can continue to meet the growing demand in the healthcare market and bring better quality solutions to Chinese patients."

Feina TU, General Manager of CR Gosun, said, "CR Gosun has been focusing on the research and development and production of anti-infective drugs for 32 years, and always adheres to the concept of strict quality of drug production, and exerts the social responsibility of a Central Enterprise to provide high-quality medicines for the public's health; we are very pleased to cooperate with Hasten, which is a highly-anticipated new force in the market, and both parties can give full play to their respective advantages and work together to make progress.”

At the same time, the executives of Hasten and CR Gosun also made in-depth exchanges on the specific content of the cooperation, the future landscape of China's healthcare industry and how to better promote the further development of both parties through cooperation. Both parties agreed that they would like to take this as a starting point to explore more cooperation opportunities and work together to improve the accessibility to healthcare for Chinese patients.

The signing of this strategic cooperation agreement is another collaboration between Hasten and China Resources Group after the strategic cooperation agreement with China Resources Pharmaceutical Commercial Group (Shanghai) Co., Ltd. signed during the 6th CIIE in November this year, which will help Hasten to benefit more patients with high-quality products, and contribute to the early realization of the “Healthy China 2030” strategy.